New Zealand markets closed

Adaptive Biotechnologies Corporation (ADPT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.3701+0.0351 (+1.50%)
As of 10:57AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 338.79M
Enterprise value 91.16M
Trailing P/E 43.96
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.98
Price/book (mrq)1.10
Enterprise value/revenue 0.54
Enterprise value/EBITDA -0.48

Trading information

Stock price history

Beta (5Y monthly) 1.24
52-week change 3-72.82%
S&P500 52-week change 321.23%
52-week high 39.0800
52-week low 32.2800
50-day moving average 33.3891
200-day moving average 34.8597

Share statistics

Avg vol (3-month) 31.63M
Avg vol (10-day) 32.38M
Shares outstanding 5145.09M
Implied shares outstanding 6145.09M
Float 896.82M
% held by insiders 12.83%
% held by institutions 196.07%
Shares short (28 Mar 2024) 49.1M
Short ratio (28 Mar 2024) 45.8
Short % of float (28 Mar 2024) 48.04%
Short % of shares outstanding (28 Mar 2024) 46.27%
Shares short (prior month 29 Feb 2024) 48.77M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -132.28%
Operating margin (ttm)-99.68%

Management effectiveness

Return on assets (ttm)-16.60%
Return on equity (ttm)-58.34%

Income statement

Revenue (ttm)170.28M
Revenue per share (ttm)1.18
Quarterly revenue growth (yoy)-17.10%
Gross profit (ttm)N/A
EBITDA -179.38M
Net income avi to common (ttm)-225.25M
Diluted EPS (ttm)-1.5600
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)346.4M
Total cash per share (mrq)2.39
Total debt (mrq)229.43M
Total debt/equity (mrq)74.42%
Current ratio (mrq)4.66
Book value per share (mrq)2.13

Cash flow statement

Operating cash flow (ttm)-156.32M
Levered free cash flow (ttm)-81.95M